Sequent Scientific Q3 sales surge, merger on track

Sequent Scientific (BSE: SEQUENT) announced a robust Q3 FY25, with consolidated revenues reaching INR3,908 million, an 18.7% increase year-over-year. The company's formulations business led the growth, recording INR3,008 million in revenue, up 19.2%. EBITDA pre-ESOP for the quarter was INR494 million, representing a 64% increase. The company reported cumulative PBT growth of nearly 150% compared to the same period last year. Sequent highlighted strong performance in emerging markets, particularly Turkey, and expansion in Latin America. The merger with Viyash Life Sciences is progressing as planned, with CCI approval already secured and SEBI approval expected soon. Viyash reported a 19% revenue increase to INR384 crores and adjusted EBITDA growth of 68%. Sequent expects continued revenue and EBITDA growth, driven by strategic initiatives, cost optimization, and synergies from the Viyash merger.